Letermovir Prophylaxis for Cytomegalovirus Infection in Adult Allogeneic Stem Cell Transplantation: A Retrospective Analysis From a Lower-Middle-Income Country
No statistically significant differences were observed between innovator and bioequivalent letermovir formulations with respect to safety or CMV outcomes. Availability of a cost-effective bioequivalent formulation may substantially expand access to CMV prophylaxis, supporting improved transplant outcomes in high-burden LMICs.
Authors
- Swati Bhayana (ORCID: https://orcid.org/0000-0003-3783-8846)
- Vikas Dua
- Anusha Swaminathan
- Nikhil Kumar
- Neha Rastogi (ORCID: https://orcid.org/0000-0003-4699-6723)
- Suyash Bharat (ORCID: https://orcid.org/0000-0002-0743-320X)
- Ashutosh Panda
- Kapil Chahal
- Anindita Paul
- Shrinidhi Nathany
- Onyeaghala Chizaram
- Rachit Agrawal
- Rahul Bhargava
Institutions
- University of Port Harcourt Teaching Hospital (NG)
- Shree Guru Gobind Singh Tricentenary University (IN)
- Fortis Memorial Research Institute (IN)
- Zydus Lifesciences Limited (India) (IN)
- International Centre for Genetic Engineering and Biotechnology (IN)
Publication Details
- Journal
- Cureus
- Published
- 2026-01-23
- DOI
- https://doi.org/10.7759/cureus.102136
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00